Biotech VC

The venture landscape has changed in general, and this is also true in Biotech.
A new crop of VC investors in the sector have been taking share from more established players in Series A funding markets.
These comprise techbio, crossover and corporate VCs.
What is interesting is the downturn has actually seen them stand their ground.